A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

Exclusion Criteria

• •Co-existing Condition:
• •Subjects with the following symptoms or conditions are excluded:
• •Positive PPD.
• •Syphilis, gonorrhea, or any other sexually transmitted diseases (including chlamydia or pelvic inflammatory disease).
• •Subjects with the following prior conditions are excluded:
• •History of immunodeficiency, chronic illness, or use of immunosuppressive medications.
• •Syphilis, gonorrhea, or any other sexually transmitted diseases (including chlamydia or pelvic inflammatory disease) in the past 6 months.
• •Prior Treatment:
• •Excluded:
• •Prior blood transfusions or cryoprecipitates within the past 6 months.
• •Identifiable high-risk behavior for HIV infection (as determined by prescreening questions designed to identify risk factors for HIV infection), including:
• •Any history of IV drug use.
• •Syphilis, gonorrhea, or any other sexually transmitted diseases (including chlamydia or pelvic inflammatory disease) in the past 6 months.
• •More than two sexual partners, or sexual contact with a high-risk partner, in the past 6 months.